12/11
07:17 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Cantor Fitzgerald to a "hold" rating.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Cantor Fitzgerald to a "hold" rating.
12/9
06:22 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
12/9
06:22 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
12/9
12:54 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
11/7
08:36 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
11/6
10:58 am
beam
Rating for BEAM
Low
Report
Rating for BEAM
11/6
10:58 am
beam
Rating for BEAM
Low
Report
Rating for BEAM
11/6
07:32 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $39.00 price target on the stock, up previously from $27.00.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $39.00 price target on the stock, up previously from $27.00.
11/6
07:26 am
beam
Rating for BEAM
Medium
Report
Rating for BEAM
11/5
06:24 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
High
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
11/5
06:24 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
High
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
10/16
10:28 am
beam
Rating for BEAM
Low
Report
Rating for BEAM
10/16
10:28 am
beam
Rating for BEAM
Low
Report
Rating for BEAM
10/16
08:44 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
10/16
08:44 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.